Indian Journal of Hematology and Blood Transfusion

, Volume 30, Supplement 1, pp 202–204

Autologous Immune Enhancement Therapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  • Revathi Raj
  • M. Deenadayalan
  • G. Vimal Kumar
  • Vipin Khandelwal
  • Karuna Sri
  • Rajappa Senthilkumar
  • Samuel J. K. Abraham
  • Terunuma Hiroshi
Case Report

DOI: 10.1007/s12288-013-0327-3

Cite this article as:
Raj, R., Deenadayalan, M., Vimal Kumar, G. et al. Indian J Hematol Blood Transfus (2014) 30: 202. doi:10.1007/s12288-013-0327-3

Abstract

Advances in current treatment regimens in childhood acute lymphoblastic leukemia (ALL) have resulted in cure rates of 75–80 %. Some molecular genetic abnormalities confer a poor prognosis. Of these, the chromosomal translocation t (9;22)—Philadelphia chromosome is associated with the worst outcome in childhood ALL. Optimal therapy for this variant of ALL includes chemotherapy as per high risk schedule, imatinib and early stem cell transplantation. We report here the successful natural killer cell-based autologous immune enhancement therapy along with chemotherapy and imatinib in a patient with Philadelphia chromosome positive ALL.

Copyright information

© Indian Society of Haematology & Transfusion Medicine 2014

Authors and Affiliations

  • Revathi Raj
    • 1
  • M. Deenadayalan
    • 1
  • G. Vimal Kumar
    • 1
  • Vipin Khandelwal
    • 1
  • Karuna Sri
    • 1
  • Rajappa Senthilkumar
    • 2
  • Samuel J. K. Abraham
    • 3
  • Terunuma Hiroshi
    • 4
  1. 1.Pediatric Hematology, Oncology and Marrow Transplantation UnitApollo Speciality HospitalsChennaiIndia
  2. 2.Nichi-In Centre for Regenerative MedicineChennaiIndia
  3. 3.Faculty of MedicineYamanashi UniversityChuoJapan
  4. 4.Biotherapy Institute of JapanTokyoJapan